• Continued strong sales momentum for MetaXplore in Australia, with Q2 sales up 195% vs PCP
• MetaPanel sales building across Australia through Sonic Healthcare network, with December being a record sales month
• MetaXplore early access program in UK delivering clinician referral rates consistent with Australia

Microba Life Sciences Limited (ASX: MAP) has reported a strong Q2 FY25, with continued growth in its testing business led by the MetaXplore test in Australia. Cash receipts were $3.87m, up 109% vs the previous corresponding period (PCP), while H1 FY25 revenue reached $8.08m, up 147% vs PCP. In Australia, MetaXplore sales grew 195% vs PCP to 2,560 tests in Q2, driven by an increase in both ordering clinicians and orders per clinician. The company's MetaPanel test also saw strong adoption, with 575 tests sold since launch and a record sales month in December.In the UK, Microba's Invivo Clinical business is transitioning to a new growth phase, with the MetaXplore early access program delivering clinician referral rates consistent with Australia. This has provided validation to accelerate the program and move towards full market access in H2 FY25.Microba remains focused on executing its testing and therapeutic business strategies. The company is also continuing to progress its inflammatory bowel disease program, with MAP 315 advancing towards a Phase 2 clinical trial, and its immuno-oncology and autoimmune disease programs.The company ended the quarter with a strong balance sheet, holding $17.3m in cash or equivalents.

Microba reported H1 FY25 revenue of $8.08m, up 147% vs PCP. The company did not provide any specific forward-looking financial guidance.

Microba is accelerating its UK expansion with the MetaXplore early access program, which is expected to support full market access in H2 FY25. The company also continues to progress its therapeutic programs, with MAP 315 advancing towards a Phase 2 clinical trial in inflammatory bowel disease.